Affinity Asset Advisors LLC Buys 5,229 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Affinity Asset Advisors LLC increased its position in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) by 2.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 263,817 shares of the company’s stock after buying an additional 5,229 shares during the quarter. Affinity Asset Advisors LLC owned about 0.46% of Cullinan Therapeutics worth $4,601,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Swiss National Bank lifted its position in shares of Cullinan Therapeutics by 19.9% during the fourth quarter. Swiss National Bank now owns 46,300 shares of the company’s stock valued at $472,000 after purchasing an additional 7,700 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Cullinan Therapeutics during the 4th quarter worth approximately $356,000. Quest Partners LLC purchased a new position in shares of Cullinan Therapeutics in the 4th quarter worth approximately $179,000. NEOS Investment Management LLC purchased a new stake in shares of Cullinan Therapeutics during the fourth quarter valued at approximately $162,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in Cullinan Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 529,877 shares of the company’s stock worth $5,399,000 after acquiring an additional 91,132 shares during the period. Institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Stock Performance

CGEM stock opened at $17.65 on Wednesday. The firm has a 50 day moving average of $18.09 and a 200-day moving average of $19.25. Cullinan Therapeutics, Inc. has a 12 month low of $7.64 and a 12 month high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.02). On average, analysts anticipate that Cullinan Therapeutics, Inc. will post -3.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on CGEM shares. HC Wainwright restated a “buy” rating and issued a $28.00 price objective on shares of Cullinan Therapeutics in a research note on Monday, September 16th. William Blair reissued an “outperform” rating on shares of Cullinan Therapeutics in a research report on Monday, June 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Cullinan Therapeutics in a report on Wednesday, September 18th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $32.00.

Insider Activity at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $18.09, for a total value of $144,720.00. Following the transaction, the insider now directly owns 115,942 shares in the company, valued at approximately $2,097,390.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.07% of the stock is owned by corporate insiders.

Cullinan Therapeutics Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.